Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut Albrecht

Showing results (11-20 of 88) with videos related to

Pageof 9
Sort By:
Chest|January 7, 2011
Vancomycin treatment vs comparator drugsHelmut Albrecht
AIDS Clinical Care|May 6, 2004
Report from the 11th conference on retroviruses and opportunistic infections. HepatitisHelmut Albrecht
Journal Watch. AIDS Clinical Care|May 13, 2010
Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. ALTAIR--the end of NRTI-only regimesHelmut Albrecht
AIDS Clinical Care|March 11, 2009
Report from the 2008 joint ICAAC/IDSA meeting. More on raltegravir: resistance and mechanisms of actionHelmut Albrecht
AIDS Clinical Care|April 11, 2008
Report from the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. HLA B-5701 and abacavir hypersensitivityHelmut Albrecht
Journal Watch. AIDS Clinical Care|July 14, 2010
Raltegravir--beauty and the beast. Both the advantages and the limitations of this integrase inhibitor were evident this yearHelmut Albrecht
AIDS Clinical Care|February 19, 2005
Top stories of 2004. To 3TC or not to 3TC?Helmut Albrecht
AIDS Clinical Care|March 10, 2009
Report from the 15th Retrovirus Conference. Racial disparities in outcomesHelmut Albrecht
AIDS Clinical Care|March 10, 2009
Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202Helmut Albrecht
Journal Watch. AIDS Clinical Care|June 24, 2009
Report from the 16th Conference on Retroviruses and Opportunistic Infections. SWITCHMRK: an avoidable raltegravir disasterHelmut Albrecht
Pageof 9

Showing results (11-20 of 88) with videos related to

Sort By:
Pageof 9
Chest|January 7, 2011
Vancomycin treatment vs comparator drugsHelmut Albrecht
AIDS Clinical Care|May 6, 2004
Report from the 11th conference on retroviruses and opportunistic infections. HepatitisHelmut Albrecht
Journal Watch. AIDS Clinical Care|May 13, 2010
Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. ALTAIR--the end of NRTI-only regimesHelmut Albrecht
AIDS Clinical Care|March 11, 2009
Report from the 2008 joint ICAAC/IDSA meeting. More on raltegravir: resistance and mechanisms of actionHelmut Albrecht
AIDS Clinical Care|April 11, 2008
Report from the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. HLA B-5701 and abacavir hypersensitivityHelmut Albrecht
Journal Watch. AIDS Clinical Care|July 14, 2010
Raltegravir--beauty and the beast. Both the advantages and the limitations of this integrase inhibitor were evident this yearHelmut Albrecht
AIDS Clinical Care|February 19, 2005
Top stories of 2004. To 3TC or not to 3TC?Helmut Albrecht
AIDS Clinical Care|March 10, 2009
Report from the 15th Retrovirus Conference. Racial disparities in outcomesHelmut Albrecht
AIDS Clinical Care|March 10, 2009
Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202Helmut Albrecht
Journal Watch. AIDS Clinical Care|June 24, 2009
Report from the 16th Conference on Retroviruses and Opportunistic Infections. SWITCHMRK: an avoidable raltegravir disasterHelmut Albrecht
Pageof 9